| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | COL3 |
| Uniprot No | Q9SK53 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-294aa |
| 氨基酸序列 | MASSSRLCDSCKSTAATLFCRADAAFLCGDCDGKIHTANKLASRHERVWLCEVCEQAPAHVTCKADAAALCVTCDRDIHSANPLSRRHERVPITPFYDAVGPAKSASSSVNFVDEDGGDVTASWLLAKEGIEITNLFSDLDYPKIEVTSEENSSGNDGVVPVQNKLFLNEDYFNFDLSASKISQQGFNFINQTVSTRTIDVPLVPESGGVTAEMTNTETPAVQLSPAEREARVLRYREKRKNRKFEKTIRYASRKAYAEMRPRIKGRFAKRTDSRENDGGDVGVYGGFGVVPSF |
| 预测分子量 | 32,3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于COL3重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**: "Production of recombinant human type III collagen in the yeast Pichia pastoris"
**作者**: Yang C, et al.
**摘要**: 该研究开发了利用毕赤酵母高效表达重组人III型胶原蛋白的方法，优化了发酵条件以获得高产量，并证实重组蛋白具备天然胶原的结构与生物活性，适用于生物材料领域。
2. **文献名称**: "Recombinant collagen III modulates fibroblast adhesion and promotes wound healing in diabetic mice"
**作者**: Smith RJ, et al.
**摘要**: 研究证明重组III型胶原蛋白通过增强成纤维细胞黏附和迁移，显著加速糖尿病小鼠皮肤伤口愈合，提示其在慢性创面治疗中的潜在应用价值。
3. **文献名称**: "Biomechanical properties of tissue-engineered cartilage using recombinant type III collagen scaffolds"
**作者**: Lee H, et al.
**摘要**: 该文献评估了重组III型胶原支架在软骨组织工程中的应用，结果显示其优异生物相容性和力学性能，支持软骨细胞增殖及细胞外基质分泌，为关节修复提供新策略。
注：以上文献信息为基于领域知识的模拟示例，实际引用时建议通过PubMed或Web of Science核实具体文献。
COL3 recombinant protein is a engineered form of human collagen type III, a crucial structural component of the extracellular matrix (ECM). Collagen III, encoded by the COL3A1 gene, is a fibrillar collagen primarily found in elastic tissues such as skin, blood vessels, and internal organs. It works synergistically with collagen I to maintain tissue integrity, flexibility, and tensile strength. Recombinant COL3 is produced through genetic engineering techniques, typically by expressing the COL3A1 gene in heterologous systems like mammalian cells (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications, particularly the hydroxylation of proline and lysine residues essential for triple-helical structure formation.
This recombinant protein has gained attention in biomedical research due to its role in tissue remodeling, wound healing, and vascular stability. It serves as a critical tool for studying connective tissue disorders such as vascular Ehlers-Danlos syndrome (vEDS), where COL3A1 mutations cause fragile blood vessels and organ rupture. Researchers utilize recombinant COL3 to establish disease models, screen therapeutic compounds, and develop collagen-based biomaterials for regenerative medicine. Compared to animal-derived collagen, recombinant versions offer batch-to-batch consistency, reduced immunogenicity, and customization potential through molecular modifications. Recent advances in expression systems have improved yield and purity, enabling applications in 3D bioprinting, organoid development, and engineered tissue constructs. However, challenges remain in replicating the complex quaternary structure of native collagen fibrils, driving ongoing optimization of production platforms.
×
